FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344997601> ?p ?o ?g. }

• W2344997601 abstract "Dear Editor,The WHO 2008 classification of myeloid neoplasms lists the following three diagnostic criteria for AML with myelodysplasia-related changes (MRC): AML arising from a previously diagnosed myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN), AML with an MDS-related cytogenetic abnormality, and AML with multi-lineage dysplasia [1]. However, a history of Philadelphia chromosome-negative MPN (Ph-MPN) does not warrant a diagnosis of AML with MRC. Here, we demonstrate that AML evolving from Ph-MPNs (MPN-AML) has similar cytogenetic characteristics and prognosis to AML evolving from MDS or MDS/MPN (MDS-AML).We identified 103 patients in our bone marrow archive who were diagnosed with AML that evolved from MDS (N=72), MDS/MPN (N=10), or Ph-MPN (N=21) from January 2006 to December 2014. The underlying Ph-MPNs included 13 (61.9%) cases of primary myelofibrosis (PMF), five (23.8%) of essential thrombocythemia (ET), and three (14.3%) of polycythemia vera (PV). MDS-related cytogenetic abnormalities were identified in 31 of 82 (37.8%) MDS-AML patients and in 12 of 21 (57.1%) patients with MPN-AML (P=0.175). The two most common abnormalities were a complex karyotype involving -5/del(5q) and isolated -7/del(7q) in all patients, without significant differences among patient groups (Fig. 1). Multi-lineage dysplasia was more often identified in patients with MDS-AML (28, 34.1%) than in patients with MPN-AML (2, 9.5%; P=0.031). Overall, 13 (61.9%) patients with MPN-AML were diagnosed with AML with MRC on the basis of cytogenetics or cytomorphology. Two patients with PMF received cytotoxic therapy before transformation of PMF to AML. During their progression to AML, one patient had a normal karyotype and the other had a complex karyotype, with both -5 and del(7q) already present during the PMF stage. The median overall survival (OS) and relapse-free survival (RFS) were 7.4 (5.2-9.2) and 22.5 (5.9-39.0) months, respectively, for patients with MDS-AML, and were 4.9 (1.3-11.9) and 4.0 (3.2-12.4) months, respectively, for those with MPN-AML. However, there were no differences in the OS (P=0.162) and RFS (P= 0.467) between the 2 patient groups (Fig. 2A). Among the MPN-AML patients, those with MRC features had a shorter OS than those without MRC (P=0.008; Fig. 2B).Fig. 1The proportion and distribution of individual cytogenetic abnormalities sufficient to diagnose AML with myelodysplasia-related changes in the study patients. No statistical differences were seen between the frequencies of -5/del(5q) in complex karyotypes ...Fig. 2Overall survival of the study patients. (A) Overall survival of patients with MDS-AML (N=82) and those with MPN-AML (N=21). There was no significant difference between overall survival rates in the 2 patient groups. (B) Overall survival of MPN-AML patients ...The patients with AML with MRC had significantly poorer clinical outcomes than those with not-otherwise-specified AML [2]. Similar to patients with MDS transforming to AML, a substantial proportion of PMF patients transform to AML [3]. Moreover, even patients with PV or ET can develop AML without an intermediate stage of myelofibrosis. The leukemic transformation in Ph-MPN is associated with a uniformly poor prognosis [3]. From this perspective, our current analysis showed that the majority of patients with MPN-AML were diagnosed with AML with MRC, mainly on the basis of cytogenetic abnormalities, and the difference between the outcomes of the patients with MDS-AML and those with MPN-AML was not significant. Our most noteworthy finding was that the cytogenetic patterns were very similar between these two patient groups. A complex karyotype with multiple chromosomal changes was the dominant cytogenetic abnormality in both groups, consistent with previous findings for patients with MPN-blast phase or AML with MRC [3,4,5,6,7]. Of note, a recent study reported that the involvement of del(5q) in complex karyotypes was associated with an extremely adverse prognosis in newly diagnosed MDS patients, which highlights the critical role of del(5q) as the primary event leading to chromosomal instability, susceptibility to rearrangements, and genomic damage [8]. Thus, the previously mentioned cytogenetic pattern of MPN-AML could explain, at least in part, the adverse clinical outcomes that were comparable to those of patients with MDS-AML. According to a recent epidemiologic study, secondary AML (sAML) occurring after non-MDS was associated with reduced survival across age and cytogenetic risk groups, whereas previous MDS or therapy-related AML did not impact overall outcomes among patients older than 60 yr of age and with an adverse karyotype [9]. Among patients with non-MDS-sAML, 73.8% had Ph-MPNs. These results are in line with our findings of poor outcomes for patients with MPN-AML, but suggest that the biological mechanisms involved in the leukemic transformation of Ph-MPNs to AML may be different from those involved in the transformation of MDS to AML.Our findings indicate that the majority of patients with MPN-AML were initially diagnosed with AML with MRC, and these patients showed cytogenetic distributions and clinical outcomes similar to those with MDS-AML. From a clinical viewpoint, these findings suggest that patients with MPN-AML or MDS-AML require therapeutic modalities different from those with de novo AML, in order to improve their outcomes." @default.
• W2344997601 created "2016-06-24" @default.
• W2344997601 creator A5011850505 @default.
• W2344997601 creator A5029347173 @default.
• W2344997601 creator A5044342301 @default.
• W2344997601 creator A5045497740 @default.
• W2344997601 creator A5054566986 @default.
• W2344997601 creator A5083302070 @default.
• W2344997601 creator A5089043882 @default.
• W2344997601 creator A5091222657 @default.
• W2344997601 date "2016-07-01" @default.
• W2344997601 modified "2023-10-16" @default.
• W2344997601 title "Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms" @default.
• W2344997601 cites W1534069493 @default.
• W2344997601 cites W1965530514 @default.
• W2344997601 cites W2034352781 @default.
• W2344997601 cites W2053584669 @default.
• W2344997601 cites W2070399140 @default.
• W2344997601 cites W2083502488 @default.
• W2344997601 cites W2086858024 @default.
• W2344997601 cites W2111724321 @default.
• W2344997601 doi "https://doi.org/10.3343/alm.2016.36.4.377" @default.
• W2344997601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4855061" @default.
• W2344997601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27139614" @default.
• W2344997601 hasPublicationYear "2016" @default.
• W2344997601 type Work @default.
• W2344997601 sameAs 2344997601 @default.
• W2344997601 citedByCount "0" @default.
• W2344997601 crossrefType "journal-article" @default.
• W2344997601 hasAuthorship W2344997601A5011850505 @default.
• W2344997601 hasAuthorship W2344997601A5029347173 @default.
• W2344997601 hasAuthorship W2344997601A5044342301 @default.
• W2344997601 hasAuthorship W2344997601A5045497740 @default.
• W2344997601 hasAuthorship W2344997601A5054566986 @default.
• W2344997601 hasAuthorship W2344997601A5083302070 @default.
• W2344997601 hasAuthorship W2344997601A5089043882 @default.
• W2344997601 hasAuthorship W2344997601A5091222657 @default.
• W2344997601 hasBestOaLocation W23449976011 @default.
• W2344997601 hasConcept C126322002 @default.
• W2344997601 hasConcept C143998085 @default.
• W2344997601 hasConcept C2775894508 @default.
• W2344997601 hasConcept C2778729363 @default.
• W2344997601 hasConcept C2778837598 @default.
• W2344997601 hasConcept C2779282312 @default.
• W2344997601 hasConcept C2780007613 @default.
• W2344997601 hasConcept C2780076729 @default.
• W2344997601 hasConcept C2780817109 @default.
• W2344997601 hasConcept C2781057849 @default.
• W2344997601 hasConcept C2781107747 @default.
• W2344997601 hasConcept C71924100 @default.
• W2344997601 hasConcept C90924648 @default.
• W2344997601 hasConceptScore W2344997601C126322002 @default.
• W2344997601 hasConceptScore W2344997601C143998085 @default.
• W2344997601 hasConceptScore W2344997601C2775894508 @default.
• W2344997601 hasConceptScore W2344997601C2778729363 @default.
• W2344997601 hasConceptScore W2344997601C2778837598 @default.
• W2344997601 hasConceptScore W2344997601C2779282312 @default.
• W2344997601 hasConceptScore W2344997601C2780007613 @default.
• W2344997601 hasConceptScore W2344997601C2780076729 @default.
• W2344997601 hasConceptScore W2344997601C2780817109 @default.
• W2344997601 hasConceptScore W2344997601C2781057849 @default.
• W2344997601 hasConceptScore W2344997601C2781107747 @default.
• W2344997601 hasConceptScore W2344997601C71924100 @default.
• W2344997601 hasConceptScore W2344997601C90924648 @default.
• W2344997601 hasLocation W23449976011 @default.
• W2344997601 hasLocation W23449976012 @default.
• W2344997601 hasLocation W23449976013 @default.
• W2344997601 hasOpenAccess W2344997601 @default.
• W2344997601 hasPrimaryLocation W23449976011 @default.
• W2344997601 hasRelatedWork W2037525802 @default.
• W2344997601 hasRelatedWork W2042702562 @default.
• W2344997601 hasRelatedWork W2048952699 @default.
• W2344997601 hasRelatedWork W2095662532 @default.
• W2344997601 hasRelatedWork W2246375256 @default.
• W2344997601 hasRelatedWork W2323897006 @default.
• W2344997601 hasRelatedWork W2398943911 @default.
• W2344997601 hasRelatedWork W2520871879 @default.
• W2344997601 hasRelatedWork W3035776639 @default.
• W2344997601 hasRelatedWork W3111068247 @default.
• W2344997601 isParatext "false" @default.
• W2344997601 isRetracted "false" @default.
• W2344997601 magId "2344997601" @default.
• W2344997601 workType "article" @default.